Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MYO1D divergent transcript (not a recognized canonical name) (MYO1D-DT)
- Target
- MYO1D-DT
- Molecular classification
- Other (if assumed to be a long non-coding RNA; not validated)
01
Overview
There is no validated or widely accepted description of "MYO1D divergent transcript" (MYO1D-DT) as a gene, transcript, long non-coding RNA (lncRNA), or protein in lung adenocarcinoma or any other disease context. The mentioned aliases and functional claims do not align with current scientific knowledge or database records. While MYO1D (Myosin ID) is a recognized gene, there are no validated reports of a divergent transcript (DT) functioning as a biomarker, therapeutic target, or known biological regulator in chemotherapy resistance or any other disease process. Any connection between MYO1D and lncRNAs related to lung cancer, specifically under the name lncCRLA or MYO1D-DT, appears to be unsupported by the scientific literature and standard gene/transcript nomenclature guidelines[4]. If you require data on the function of canonical MYO1D or actual lncRNAs implicated in chemotherapy resistance in lung adenocarcinoma, please specify and request those entities directly for validated information.
- Other names
- lncCRLAlncRNA-related chemotherapy resistance in lung adenocarcinomaMYO1D-DT
Beyond the preview
Go deeper on MYO1D divergent transcript (not a recognized canonical name) (MYO1D-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYO1D divergent transcript (not a recognized canonical name) (MYO1D-DT).